Immune-Related Polyneuropathy and Generalized Myoclonus Associated with Pembrolizumab in a Patient with Metastatic Melanoma: A Case Report and Literature Review

Main Article Content

Caio Semensato Borges
Caio Augusto Dantas Pereira
Lucas Ravagnani Silva
Jorge Alberto Martins Pentiado Junior
Jonatas Crispim Magalhães de Oliveira
https://orcid.org/0009-0004-4879-3254
Sérgio Vicente Serrano
Thales Pardini Fagundes

Abstract

Pembrolizumab is used to treat metastatic melanoma but may cause neurological immune-related adverse events involving the peripheral and central nervous systems. We report a 45-year-old man who developed painful sensory-motor polyneuropathy and clinically identified negative myoclonus during pembrolizumab-based treatment. Initial cerebrospinal fluid analysis showed lymphocytic pleocytosis and elevated protein, followed by albuminocytologic dissociation on repeat sampling. Electroencephalography (EEG) was unavailable. The initial episode was classified clinically as grade 2 and improved after corticosteroids and symptomatic treatment. Following pembrolizumab reintroduction, severe neurological symptoms recurred in September 2024, with a modified Rankin Scale score of 4, leading to permanent discontinuation. An August 2025 electrophysiological report described persistent severe mixed axonal and demyelinating sensory-motor neuropathy. The patient subsequently developed systemic and brain metastatic progression and died in April 2026. The temporal course supports suspected treatment-related neurological toxicity, but incomplete etiological and electrophysiological characterization limits causal attribution, particularly for myoclonus.

Article Details

How to Cite
Borges, C. S., Pereira, C. A. D., Silva, L. R., Pentiado Junior, J. A. M., de Oliveira, J. C. M., Serrano, S. V., & Fagundes, T. P. (2026). Immune-Related Polyneuropathy and Generalized Myoclonus Associated with Pembrolizumab in a Patient with Metastatic Melanoma: A Case Report and Literature Review. Brazilian Journal of Case Reports, 6(1), bjcr237. https://doi.org/10.52600/2763-583X.bjcr.2026.6.1.bjcr237
Section
Clinical Case Reports
Author Biographies

Caio Semensato Borges, Department of Medical Oncology, Barretos Cancer Hospital

Department of Medical Oncology, Barretos Cancer Hospital, Barretos, São Paulo, Brazil.

Caio Augusto Dantas Pereira, Department of Medical Oncology, Barretos Cancer Hospital

Department of Medical Oncology, Barretos Cancer Hospital, Barretos, São Paulo, Brazil.

Lucas Ravagnani Silva, Department of Medical Oncology, Barretos Cancer Hospital

Department of Medical Oncology, Barretos Cancer Hospital, Barretos, São Paulo, Brazil.

Jorge Alberto Martins Pentiado Junior, Department of Medical Oncology, Barretos Cancer Hospital

Department of Medical Oncology, Barretos Cancer Hospital, Barretos, São Paulo, Brazil.

Jonatas Crispim Magalhães de Oliveira, Department of Medical Oncology, Barretos Cancer Hospital

Department of Medical Oncology, Barretos Cancer Hospital, Barretos, São Paulo, Brazil.

Sérgio Vicente Serrano, Department of Medical Oncology, Barretos Cancer Hospital

Department of Medical Oncology, Barretos Cancer Hospital, Barretos, São Paulo, Brazil.

Thales Pardini Fagundes, Department of Neuro-Oncology, Barretos Cancer Hospital

Department of Neuro-Oncology, Barretos Cancer Hospital, Barretos, São Paulo, Brazil.

References

Instituto Nacional de Câncer José Alencar Gomes da Silva. Estimativa 2023: incidência de câncer no Brasil. Rio de Janeiro: INCA; 2022 [acesso 2024 maio 1]. Disponível em: https://www.inca.gov.br/publicacoes/livros/estimativa-2023-incidencia-de-cancer-no-brasil

Pestronk A. Neuromuscular Disease Center. St. Louis: Washington University School of Medicine; 1987-2024 [acesso 2024 maio 1]. Disponível em: https://neuromuscular.wustl.edu

McCormack SM, Hamad A. Pembrolizumab-Induced Myasthenia Gravis and Peripheral Neuropathy: A Case Series. Cureus. 2023 Sep 6;15(9):e44799. doi: 10.7759/cureus.44799.

Albarrán V, Chamorro J, Rosero DI, Saavedra C, Soria A, Carrato A, et al. Neurologic Toxicity of Immune Checkpoint Inhi-bitors: A Review of Literature. Front Pharmacol. 2022 Feb 14;13:774170. doi: 10.3389/fphar.2022.774170.

Diamantopoulos PT, Tsatsou K, Benopoulou O, Anastasopoulou A, Gogas H. Inflammatory Myopathy and Axonal Neuro-pathy in a Patient With Melanoma Following Pembrolizumab Treatment. J Immunother. 2017 Jul/Aug;40(6):221-223. doi: 10.1097/CJI.0000000000000172.

Cuzzubbo S, Javeri F, Tissier M, Roumi A, Barlog C, Doridam J, et al. Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature. Eur J Cancer. 2017 Mar;73:1-8. doi: 10.1016/j.ejca.2016.12.001.

Cho J, Kim HS, Ku BM, Choi YL, Cristescu R, Han J, et al. Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II Trial. J Clin Oncol. 2019 Aug 20;37(24):2162-2170. doi: 10.1200/JCO.2017.77.3184.

Gallagher A, Murphy M, McDermott R, Alexander M, O'Dowd S. Pembrolizumab-Induced Steroid-Responsive Myoclonus. Mov Disord Clin Pract. 2022 May 3;9(4):546-550. doi: 10.1002/mdc3.13453.

Johnson DB, Manouchehri A, Haugh AM, Quach HT, Balko JM, Lebrun-Vignes B, et al. Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study. J Immunother Cancer. 2019;7:134. doi:10.1186/s40425-019-0617-x.

Dinoto A, Trentinaglia M, Carta S, Mantovani E, Ferrari S, Tamburin S, et al. Autoimmune Movement Disorders Complica-ting Treatment with Immune Checkpoint Inhibitors. Mov Disord Clin Pract. 2024;11(5):543-549. doi:10.1002/mdc3.14003.

Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol. 2021;39(36):4073-4126. doi:10.1200/JCO.21.01440.